Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 11/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | LATS1 | O95835 | 1/20 | 0.44 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619226 | 0.85 | GBA1 (0.41) | GBA1ADORA3ADORA2AADORA1HDAC2 | |
| SCHEMBL29619254 | 0.83 | HDAC1 (0.52) | GBA1ADORA3ADORA2AADORA1HDAC2 | |
| SCHEMBL29619245 | 0.81 | GBA1 (0.61) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL29363070 | 0.79 | GBA1 (0.48) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL22428627 | 0.79 | GBA1 (0.48) | GBA1ADORA3ADORA2AADORA1LATS1 | |
| SCHEMBL19365312 | 0.79 | GBA1 (0.42) | GBA1ADORA3ADORA2AADORA1HDAC1 | |
| SCHEMBL16084146 | 0.78 | GBA1 (0.49) | GBA1ADORA3ADORA2AADORA1CDK2 | |
| SCHEMBL22428619 | 0.77 | ADORA1 (0.46) | ADORA3ADORA2AADORA1HDAC2HDAC1 | |
| SCHEMBL29363115 | 0.77 | ADORA1 (0.46) | ADORA3ADORA2AADORA1HDAC2HDAC1 | |
| SCHEMBL22428735 | 0.76 | GBA1 (0.45) | GBA1ADORA3ADORA2AADORA1LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938340-B1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEV LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | GBA1 1015/4885ADORA3 1623/4885ADORA2A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.